SCHEMBL6296504

SCHEMBL6296504

CC(=N/Oc1ccccc1)/C(=N\O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 5/20 0.34
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
HPGD P15428 2/20 0.34
POLB P06746 1/20 0.34
XBP1 P17861 1/20 0.34
MAOB P27338 1/20 0.34
PKM P14618 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
ELANE P08246 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292707 0.86 GAA (0.39) GAACYP2C19ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL5265634 0.78 GAA (0.54) GAACYP2C19ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL5265637 0.78 GAA (0.54) GAACYP2C19ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL9254279 0.76 CES2 (0.50) ALDH1A1L3MBTL1MAPTNPC1RAB9A
SCHEMBL9175243 0.73 MAPT (0.44) GAAALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL14667496 0.72 CA4 (0.42) GAAALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL11539712 0.72 CYP2C19 (0.42) GAACYP2C19ALDH1A1L3MBTL1LMNA
SCHEMBL11539714 0.72 CYP2C19 (0.42) GAACYP2C19ALDH1A1L3MBTL1LMNA
SCHEMBL12131284 0.71 GAA (0.65) GAACYP2C19ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL189919 0.71 GAA (0.65) GAACYP2C19ALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858745-B2 Alkyl cobalt (III) dioximates and process for forming the same E. I. DU PONT DE NEMOURS AND COMPANY (US) 2005-02-22 US disclosed
US-6740618-B2 REACTIN A GLYOXIME, A COBALT SALT, AN UNSATURATED COMPOUND SUCH AS AN ALKYL ACRYLATE, AND A LEWIS BASE IN H2; USE AS A POLYMERIZATION CATALYST, ESPECIALLY IN POLYMERIZING METHYL METHACRYLATE E. I. DU PONT DE NEMOURS AND COMPANY 2004-05-25 US disclosed
US-6713427-B2 TREATING A MIXTURE OF A COBALT (II) SALT, A DIOXIME OF THE FORMULA R1-C( HORIZONTAL-LINE NOH)-C( HORIZONTAL-LINE NOH)-R2, AN ACRYLIC ESTER, A LEWIS BASE WITH MOLECULAR HYDROGEN TO FORM A COBALT DIOXIMATE COMPLEX E. I. DU PONT DE NEMOURS AND COMPANY 2004-03-30 US disclosed
US-20030149275-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2003-08-07 US disclosed
US-20030135054-A1 Alkyl cobalt(III) dioximates and process for forming the same GRIDNEV ALEXEI A (US) 2003-07-17 US disclosed
US-20030125564-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2003-07-03 US disclosed
US-6559327-B2 By reacting a cobalt salt, a dioxime such as diphenylglyoxime, a lewis base such as 1,2-dimethylimidazole, and an olefinic compound such as methyl acrylate, and treating with hydrogen; high yield, purity E. I. DU PONT DE NEMOURS AND COMPANY 2003-05-06 US disclosed
EP-1221447-A2 Alkyl Cobalt (III) Dioximates and process for forming the same E. I. du Pont de Nemours and Company (US) 2002-07-10 EP disclosed
US-20020087006-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149275-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4343/4885CYP2C19 2755/4885ALDH1A1 2250/4885
US-20030125564-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4331/4885CYP2C19 2760/4885ALDH1A1 2232/4885
US-20020087006-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4331/4885CYP2C19 2760/4885ALDH1A1 2232/4885
US-20030135054-A1 Alkyl cobalt(III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4331/4885CYP2C19 2760/4885ALDH1A1 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.